Q2 EPS Forecast for Y-mAbs Therapeutics Lowered by Analyst

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Equities researchers at Wedbush cut their Q2 2025 earnings estimates for shares of Y-mAbs Therapeutics in a research report issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.29) per share for the quarter, down from their prior estimate of ($0.25). Wedbush has a “Outperform” rating and a $23.00 price target on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.08) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.63) EPS and FY2028 earnings at ($1.78) EPS.

Several other research firms have also weighed in on YMAB. HC Wainwright dropped their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Oppenheimer dropped their price target on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday. Bank of America lowered shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a research note on Tuesday, April 22nd. Truist Financial lowered their price objective on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Morgan Stanley lowered their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.70.

Y-mAbs Therapeutics Stock Down 12.5%

YMAB opened at $3.64 on Thursday. The firm has a market cap of $164.81 million, a price-to-earnings ratio of -6.74 and a beta of 0.53. Y-mAbs Therapeutics has a fifty-two week low of $3.63 and a fifty-two week high of $16.11. The company’s 50-day moving average price is $4.50 and its 200 day moving average price is $7.26.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $20.90 million for the quarter, compared to analysts’ expectations of $19.97 million.

Insider Activity

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the business’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. The trade was a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Stonepine Capital Management LLC bought a new position in shares of Y-mAbs Therapeutics in the first quarter worth about $581,000. Jump Financial LLC raised its stake in shares of Y-mAbs Therapeutics by 14.1% in the first quarter. Jump Financial LLC now owns 38,079 shares of the company’s stock worth $169,000 after acquiring an additional 4,699 shares during the last quarter. AlphaQuest LLC raised its stake in shares of Y-mAbs Therapeutics by 43.4% in the first quarter. AlphaQuest LLC now owns 38,925 shares of the company’s stock worth $172,000 after acquiring an additional 11,790 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Y-mAbs Therapeutics in the first quarter worth about $56,000. Finally, Wellington Management Group LLP raised its stake in shares of Y-mAbs Therapeutics by 53.1% during the first quarter. Wellington Management Group LLP now owns 204,052 shares of the company’s stock worth $904,000 after buying an additional 70,789 shares during the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.